{
    "nct_id": "NCT04190446",
    "official_title": "A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer Involving Only Pelvic and/or Para-Aortic Lymph Nodes Following Primary Localized Treatment",
    "inclusion_criteria": "* Male; age >= 18 years\n* Histological confirmation of prostate adenocarcinoma\n* Recurrent prostate cancer after prior receipt of primary radiotherapy to the prostate (can also include treatment of splenic vessels [SVs] and lymph nodes [LNs]) or salvage RT to the prostate fossa (can also include prior pelvic RT)\n* Oligometastatic extent of disease\n\n  * Recurrent disease involving lymph nodes as diagnosed with choline positron emission tomography (PET)/computed tomography (CT) or other advanced PET imaging (prostate-specific membrane antigen [PSMA] or flucyclovine)\n  * Limited to pelvic and/or retroperitoneal/para-aortic lymph nodes\n* Zubrod performance score (PS) =< 1\n* Signed informed consent\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Bone or visceral metastases present\n* Lymph node metastases beyond the pelvis and/or retroperitoneum\n* Contraindications to RT (e.g., uncontrolled inflammatory bowel disease)\n* Contraindications to androgen suppression\n* Concurrent antineoplastic agents (chemotherapy)\n* Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer\n* Inability to start the radiation portion of the protocol treatment within 6 months after study enrollment\n* Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up",
    "miscellaneous_criteria": ""
}